KR20080070744A - Ａβ-관련 병리의 치료에 유용한 신규 2-아미노헤테로사이클 - Google Patents
Ａβ-관련 병리의 치료에 유용한 신규 2-아미노헤테로사이클 Download PDFInfo
- Publication number
- KR20080070744A KR20080070744A KR1020087014418A KR20087014418A KR20080070744A KR 20080070744 A KR20080070744 A KR 20080070744A KR 1020087014418 A KR1020087014418 A KR 1020087014418A KR 20087014418 A KR20087014418 A KR 20087014418A KR 20080070744 A KR20080070744 A KR 20080070744A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- heterocycloalkyl
- aryl
- heteroaryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *CC(CC(*)(*c1c(*)c(*)c(*)c(*)c11)N=C1N)c1ccccc1 Chemical compound *CC(CC(*)(*c1c(*)c(*)c(*)c(*)c11)N=C1N)c1ccccc1 0.000 description 5
- HEIFJGRZURGKCZ-UHFFFAOYSA-N COc1cc(-c2cc(C(Cc3c4[s]cc3)N=C4N)ccc2)ccc1 Chemical compound COc1cc(-c2cc(C(Cc3c4[s]cc3)N=C4N)ccc2)ccc1 HEIFJGRZURGKCZ-UHFFFAOYSA-N 0.000 description 2
- OQCXSYLQUVPNQE-UHFFFAOYSA-N CC(Cc1ccccc11)(c2cccc(-c3cccc(OC)c3)c2)N=C1N Chemical compound CC(Cc1ccccc11)(c2cccc(-c3cccc(OC)c3)c2)N=C1N OQCXSYLQUVPNQE-UHFFFAOYSA-N 0.000 description 1
- CDYVUNDCAMJLOW-UHFFFAOYSA-N CC1(CCc2cccc(-c3cccc(OC)c3)c2)Oc2ccccc2C(N)=N1 Chemical compound CC1(CCc2cccc(-c3cccc(OC)c3)c2)Oc2ccccc2C(N)=N1 CDYVUNDCAMJLOW-UHFFFAOYSA-N 0.000 description 1
- RHBKGFVBSYKCMN-UHFFFAOYSA-N CC1(c2cc(-c3cccc(OC)c3)ccc2)Oc2ccccc2C(N)=N1 Chemical compound CC1(c2cc(-c3cccc(OC)c3)ccc2)Oc2ccccc2C(N)=N1 RHBKGFVBSYKCMN-UHFFFAOYSA-N 0.000 description 1
- XTVLQYPUQPRBOS-UHFFFAOYSA-N COc1cc(-c2cccc(C(Cc3ccccc33)(c4ccccc4)N=C3N)c2)ccc1 Chemical compound COc1cc(-c2cccc(C(Cc3ccccc33)(c4ccccc4)N=C3N)c2)ccc1 XTVLQYPUQPRBOS-UHFFFAOYSA-N 0.000 description 1
- FLXYWYYKNDBERX-UHFFFAOYSA-N NC(c(cc1)c(C2)cc1-c1nnn[nH]1)=NC2(C(F)(F)F)c1ccccc1 Chemical compound NC(c(cc1)c(C2)cc1-c1nnn[nH]1)=NC2(C(F)(F)F)c1ccccc1 FLXYWYYKNDBERX-UHFFFAOYSA-N 0.000 description 1
- WQCFHXSHHQDQIO-UHFFFAOYSA-N NC(c1c(C2)cc[s]1)=NC2c1cccc(Br)c1 Chemical compound NC(c1c(C2)cc[s]1)=NC2c1cccc(Br)c1 WQCFHXSHHQDQIO-UHFFFAOYSA-N 0.000 description 1
- SUISZCALMBHJQX-UHFFFAOYSA-N O=Cc1cc(Br)ccc1 Chemical compound O=Cc1cc(Br)ccc1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73732705P | 2005-11-15 | 2005-11-15 | |
| US60/737,327 | 2005-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080070744A true KR20080070744A (ko) | 2008-07-30 |
Family
ID=38049090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087014418A Withdrawn KR20080070744A (ko) | 2005-11-15 | 2006-11-13 | Ａβ-관련 병리의 치료에 유용한 신규 2-아미노헤테로사이클 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080293709A1 (enExample) |
| EP (1) | EP1957462A4 (enExample) |
| JP (1) | JP2009520685A (enExample) |
| KR (1) | KR20080070744A (enExample) |
| CN (1) | CN101360714A (enExample) |
| AR (1) | AR056217A1 (enExample) |
| AU (1) | AU2006316256A1 (enExample) |
| BR (1) | BRPI0618607A2 (enExample) |
| CA (1) | CA2629831A1 (enExample) |
| IL (1) | IL191057A0 (enExample) |
| NO (1) | NO20082481L (enExample) |
| TW (1) | TW200804290A (enExample) |
| UY (1) | UY29919A1 (enExample) |
| WO (1) | WO2007058583A2 (enExample) |
| ZA (1) | ZA200803859B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CA2610828A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
| PE20070135A1 (es) | 2005-06-14 | 2007-03-09 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil proteasas |
| KR101052122B1 (ko) | 2005-10-25 | 2011-07-26 | 시오노기세야쿠 가부시키가이샤 | 아미노디히드로티아진 유도체 |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| EP2147914B1 (en) | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
| MX2010002938A (es) | 2007-09-24 | 2010-04-01 | Comentis Inc | Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. |
| JP2011507909A (ja) * | 2007-12-20 | 2011-03-10 | エンビボ ファーマシューティカルズ インコーポレイテッド | 四置換ベンゼン |
| MX2010013256A (es) | 2008-06-13 | 2010-12-21 | Shionogi & Co | Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa. |
| JP2012505241A (ja) | 2008-10-10 | 2012-03-01 | パーデュー・リサーチ・ファウンデーション | アルツハイマー病の治療用組成物 |
| JPWO2010047372A1 (ja) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体 |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| US8394807B2 (en) | 2008-11-20 | 2013-03-12 | Purdue Research Foundation | Quinazoline inhibitors of BACE 1 and methods of using |
| US8859590B2 (en) | 2008-12-05 | 2014-10-14 | Purdue Research Foundation | Inhibitors of BACE1 and methods for treating Alzheimer's disease |
| NZ598942A (en) | 2009-07-27 | 2014-02-28 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| JPWO2011071135A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | オキサジン誘導体 |
| JPWO2011077726A1 (ja) | 2009-12-24 | 2013-05-02 | 塩野義製薬株式会社 | ４−アミノ−１，３−チアジンまたはオキサジン誘導体 |
| EA021240B1 (ru) | 2010-06-09 | 2015-05-29 | Янссен Фармацевтика Нв | Производные 5,6-дигидро-2h-[1,4]оксазин-3-иламина в качестве ингибиторов бета-секретазы (bace) |
| CN103096977B (zh) | 2010-07-02 | 2017-02-15 | 吉利德科学公司 | 作为离子通道调节剂的稠杂环化合物 |
| CA2807904C (en) * | 2010-09-22 | 2018-09-11 | Janssen Pharmaceutica Nv | 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
| EP2634188A4 (en) * | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
| CA2816285A1 (en) * | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| US9840507B2 (en) | 2010-12-22 | 2017-12-12 | Janssen Pharmaceutica, Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
| HUE026338T2 (en) | 2011-03-01 | 2016-05-30 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
| MX340031B (es) | 2011-03-09 | 2016-06-21 | Janssen Pharmaceutica Nv | Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1-ilamina utiles como inhibidores de beta-secretasa (bace). |
| US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| TWI577670B (zh) | 2011-05-10 | 2017-04-11 | 基利科學股份有限公司 | 充當離子通道調節劑之稠合雜環化合物 |
| TWI622583B (zh) | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| EP2747769B1 (en) | 2011-08-22 | 2017-08-02 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| ES2721073T3 (es) | 2013-06-12 | 2019-07-26 | Janssen Pharmaceutica Nv | Derivados de 4-amino-6-fenil-6,7-dihidro[1,2,3]triazolo[1,5 a]pirazina como inhibidores de beta-secretasa (BACE) |
| CA2911690C (en) | 2013-06-12 | 2021-08-24 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace) |
| MX368326B (es) | 2013-06-12 | 2019-09-27 | Janssen Pharmaceutica Nv | Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace). |
| AU2015367594C1 (en) | 2014-12-18 | 2019-10-31 | Janssen Pharmaceutica Nv | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996018616A1 (en) * | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| CZ119398A3 (cs) * | 1995-10-17 | 1998-09-16 | Astra Aktiebolag | Farmaceuticky účinné sloučeniny na bázi chinazolinu |
| AU706110B2 (en) * | 1996-04-13 | 1999-06-10 | Astrazeneca Ab | Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents |
| EP2198867A1 (en) * | 2001-12-07 | 2010-06-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
| JP2008543841A (ja) * | 2005-06-14 | 2008-12-04 | シェーリング コーポレイション | 大環状複素環式アスパルチルプロテアーゼインヒビター |
-
2006
- 2006-11-08 TW TW095141352A patent/TW200804290A/zh unknown
- 2006-11-13 AU AU2006316256A patent/AU2006316256A1/en not_active Abandoned
- 2006-11-13 US US12/093,631 patent/US20080293709A1/en not_active Abandoned
- 2006-11-13 CA CA002629831A patent/CA2629831A1/en not_active Abandoned
- 2006-11-13 AR ARP060104956A patent/AR056217A1/es not_active Application Discontinuation
- 2006-11-13 CN CNA2006800511195A patent/CN101360714A/zh active Pending
- 2006-11-13 EP EP06813006A patent/EP1957462A4/en not_active Withdrawn
- 2006-11-13 WO PCT/SE2006/001283 patent/WO2007058583A2/en not_active Ceased
- 2006-11-13 JP JP2008541110A patent/JP2009520685A/ja active Pending
- 2006-11-13 KR KR1020087014418A patent/KR20080070744A/ko not_active Withdrawn
- 2006-11-13 BR BRPI0618607-6A patent/BRPI0618607A2/pt not_active IP Right Cessation
- 2006-11-14 UY UY29919A patent/UY29919A1/es not_active Application Discontinuation
-
2008
- 2008-04-27 IL IL191057A patent/IL191057A0/en unknown
- 2008-05-06 ZA ZA200803859A patent/ZA200803859B/xx unknown
- 2008-06-03 NO NO20082481A patent/NO20082481L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200803859B (en) | 2009-02-25 |
| JP2009520685A (ja) | 2009-05-28 |
| WO2007058583A3 (en) | 2007-07-05 |
| WO2007058583A2 (en) | 2007-05-24 |
| TW200804290A (en) | 2008-01-16 |
| EP1957462A2 (en) | 2008-08-20 |
| UY29919A1 (es) | 2007-06-29 |
| CN101360714A (zh) | 2009-02-04 |
| US20080293709A1 (en) | 2008-11-27 |
| AR056217A1 (es) | 2007-09-26 |
| EP1957462A4 (en) | 2010-09-15 |
| BRPI0618607A2 (pt) | 2011-09-06 |
| NO20082481L (no) | 2008-07-24 |
| CA2629831A1 (en) | 2007-05-24 |
| AU2006316256A1 (en) | 2007-05-24 |
| IL191057A0 (en) | 2008-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080070744A (ko) | Ａβ-관련 병리의 치료에 유용한 신규 2-아미노헤테로사이클 | |
| AU2007261749B2 (en) | Substituted isoindoles as bace inhibitors and their use | |
| US20090215801A9 (en) | Novel 2-Aminopyrimidinone Derivatives And Their Use | |
| CN101360716A (zh) | 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途 | |
| JP2009519221A (ja) | 新規な２−アミノ−イミダゾール−４−オン化合物、並びに認知障害、アルツハイマー病、神経変性及び認知症の治療に使用する医薬の製造におけるその使用 | |
| WO2008076043A1 (en) | Novel 2-amino-5,5-diaryl-imidazol-4-ones | |
| JP2009539975A (ja) | アミノイミダゾロン類、および、認知機能障害、アルツハイマー病、神経変性および認知症を治療するための医薬品としてのそれらの使用 | |
| JP2009520022A (ja) | 置換２−アミノピリミジン−４−オン、その薬学的組成物並びにＡβ関連病状の処置及び／又は予防におけるその使用 | |
| CN101360721A (zh) | 新颖的2-氨基嘧啶酮衍生物或2-氨基吡啶酮衍生物及其用途 | |
| CN101360722A (zh) | 新颖的2-氨基嘧啶衍生物及其用途 | |
| CN101506162B (zh) | 作为β位淀粉样前体蛋白裂解酶抑制剂的取代的异吲哚和它们的用途 | |
| HK1127034A (en) | Novel 2-aminopyrimidine derivatives and their use | |
| MX2008005985A (es) | Compuestos iv y usos de los mismos | |
| HK1127036A (en) | Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use | |
| HK1127035A (en) | Novel 2-aminopyrimidinone derivatives and their use | |
| HK1127038A (en) | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer's disease, neurodegeneration and dementia | |
| CN101506212A (zh) | 氨基-咪唑酮及其作为治疗认知缺损、阿尔兹海默病、神经变性和痴呆的药物的用途 | |
| BRPI0713463A2 (pt) | composto, formulação farmacêutica, uso de um composto, e, métodos para inibir a atividade de bace e para tratar ou prevenie uma patologia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20080613 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |